
Sanofi forms new alliance to fight zika in Brazil
pharmafile | October 27, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi, Zika
Sanofi has teamed up with Brazilian research institute Fiocruz to accelerate development of a zika vaccine.
This is another step in Sanofi’s robust plan for development of a vaccine against the mosquito-borne virus. In July, the company formed an alliance with a US Army research institute, and it intends to promote collaboration between this new trio to “increase the likelihood of successfully developing and licensing a safe and effective Zika vaccine as quickly as possible”.
“It only makes sense for the pursuit of public health that we combine our expertise and resources on zika with Fiocruz, which is ideally based in Brazil where the heart of the current zika experience lies,” said John Shiver, senior vice president for research at Sanofi’s vaccines unit.
The French manufacturer also secured $43 million from the BioMedical Advanced Research and Development Authority (BARDA) back in September.
Sanofi has also invested its expertise in other, similar viral areas, developing shots against other so-called flaviviruses, such as yellow fever, dengue and Japanese encephalitis.
Analysts are expecting a vaccine to hit the market in as little as two years.
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






